<DOC>
	<DOC>NCT00870103</DOC>
	<brief_summary>To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>≧18 years of age able to sign an informed consent and complete all required visits intends to have a cataract extraction surgery followed by implantation of a posterior chamber Intraocular lens (IOL) Intraocular Pressure (IOP) ≦ 20 millimeters mercury (mmHg) Uncontrolled glaucoma or IOP use of ocular antiinfectious during the study and within 30 days prior to the enrollment, secondary implantation or replacement of IOL in the study eye use of steroid during the study or within 14 days prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Cataract</keyword>
</DOC>